Arcadia Q2 revenue surges 175% to $3.9M; net loss improves to $0.17/share

Arcadia Biosciences, Inc.

2022-Q2 EPS reported -$0.37 revenue$7,078,000

Q2 revenue $3.9M vs $1.4M a year ago, driven by Zola and GoodWheat pasta launch.
Net loss attributable to common stockholders narrowed 28% to $3.8M ($0.17 per share) from $5.3M.
First-half 2022 revenue $7.1M, up 217%; net loss $8.3M vs $3.2M, impacted by absence of $10.2M gain on Bioceres stock in 2021.
Received $2M milestone from Bioceres for HB4 soybean approval in China; part recognized as license revenue.
Introduced Project Greenfield, a 3-year plan aiming for profitability, focusing on core brands.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.